Brown, J., Miller, A., Moxley, K., Backes, F., Nagel, C., Bender, D., … Aghajanian, C. (2020). RESULTS OF A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS BLEOMYCIN, ETOPOSIDE AND CISPLATIN FOR NEWLY DIAGNOSED AND RECURRENT CHEMONAIVE STROMAL OVARIAN TUMORS. In INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (Vol. 30, pp. A56–A56).

Brown, J., A. Miller, K. Moxley, F. Backes, C. Nagel, D. Bender, D. Miller, et al. “RESULTS OF A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS BLEOMYCIN, ETOPOSIDE AND CISPLATIN FOR NEWLY DIAGNOSED AND RECURRENT CHEMONAIVE STROMAL OVARIAN TUMORS.” In INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 30:A56–A56, 2020.

Brown J, Miller A, Moxley K, Backes F, Nagel C, Bender D, et al. RESULTS OF A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS BLEOMYCIN, ETOPOSIDE AND CISPLATIN FOR NEWLY DIAGNOSED AND RECURRENT CHEMONAIVE STROMAL OVARIAN TUMORS. In: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2020. p. A56–A56.

Brown, J., et al. “RESULTS OF A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS BLEOMYCIN, ETOPOSIDE AND CISPLATIN FOR NEWLY DIAGNOSED AND RECURRENT CHEMONAIVE STROMAL OVARIAN TUMORS.” INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol. 30, 2020, pp. A56–A56.

Brown J, Miller A, Moxley K, Backes F, Nagel C, Bender D, Miller D, Powell M, Westin S, Bonebrake A, Muller C, Secord AA, Crane E, Schorge J, Tew W, Sood A, Aghajanian C. RESULTS OF A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS BLEOMYCIN, ETOPOSIDE AND CISPLATIN FOR NEWLY DIAGNOSED AND RECURRENT CHEMONAIVE STROMAL OVARIAN TUMORS. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2020. p. A56–A56.